Literature DB >> 16701957

The dex/CRH test--is it better than the DST?

Stuart Watson1, Peter Gallagher, Margaret S Smith, I Nicol Ferrier, Allan H Young.   

Abstract

The dexamethasone suppression test (DST), frequently abnormal in mood disorder patients, is considered to measure glucocorticoid receptor-mediated negative feedback. We examined the hypothesis that the, apparently more sensitive, dexamethasone/corticotrophin-releasing-hormone (dex/CRH) test unveils subtle hypothalamic-pituitary-adrenal axis disturbance not detected by the DST in 82 patients with mood disorders and 28 controls. There was a close correlation between the cortisol responses on the two tests (r(s)=0.73, p<0.0005). However, ROC analysis revealed that the dex/CRH test had better diagnostic performance than the DST (p=0.031). The sensitivity of delta cortisol (from the dex/CRH) was 61.9% and the specificity 71.4%. The sensitivity of 1500 h cortisol (the DST) was 66.6% and the specificity was 47.6%. This suggests that the two tests measure common pathology but that the dex/CRH test has better diagnostic utility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16701957     DOI: 10.1016/j.psyneuen.2006.03.001

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  22 in total

1.  Interleukin-1β causes fluoxetine resistance in an animal model of epilepsy-associated depression.

Authors:  Eduardo A Pineda; Julie G Hensler; Raman Sankar; Don Shin; Teresa F Burke; Andréy M Mazarati
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

2.  The neuroendocrinology of childhood trauma in personality disorder.

Authors:  Royce J Lee; Jessica Hempel; Aaron Tenharmsel; Tianmin Liu; Aleksander A Mathé; Alan Klock
Journal:  Psychoneuroendocrinology       Date:  2011-06-08       Impact factor: 4.905

Review 3.  [Epigenetic mechanisms in major depression].

Authors:  G Paslakis; S Bleich; H Frieling; M Deuschle
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

Review 4.  Biomarkers of epileptogenesis: psychiatric comorbidities (?).

Authors:  Andres M Kanner; Andrey Mazarati; Matthias Koepp
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

5.  Comorbidity between epilepsy and depression: role of hippocampal interleukin-1beta.

Authors:  Andrey M Mazarati; Eduardo Pineda; Don Shin; Delia Tio; Anna N Taylor; Raman Sankar
Journal:  Neurobiol Dis       Date:  2009-11-10       Impact factor: 5.996

Review 6.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

7.  Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy.

Authors:  Andrey M Mazarati; Don Shin; Young Se Kwon; Anatol Bragin; Eduardo Pineda; Delia Tio; Anna N Taylor; Raman Sankar
Journal:  Neurobiol Dis       Date:  2009-03-11       Impact factor: 5.996

Review 8.  Neuroimmunomodulation in depression: a review of inflammatory cytokines involved in this process.

Authors:  Helena M Abelaira; Gislaine Z Réus; Fabricia Petronilho; Tatiana Barichello; João Quevedo
Journal:  Neurochem Res       Date:  2014-07-05       Impact factor: 3.996

9.  Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder.

Authors:  Rose C Mantella; Meryl A Butters; Janet A Amico; Sati Mazumdar; Bruce L Rollman; Amy E Begley; Charles F Reynolds; Eric J Lenze
Journal:  Psychoneuroendocrinology       Date:  2008-04-14       Impact factor: 4.905

Review 10.  Sex differences in stress-related psychiatric disorders: neurobiological perspectives.

Authors:  Debra A Bangasser; Rita J Valentino
Journal:  Front Neuroendocrinol       Date:  2014-04-12       Impact factor: 8.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.